Trichloroethylene

S&P Global Platts Launches LNG-Fueled TCEs, Newcastlemax Weighted Index

Retrieved on:

Thursday, February 10, 2022

Industry, TCE, Time, Sulfur oxide, NOx, GNU, Fuel, Society, Amalgamated Society of Gas Workers, Brickmakers and General Labourers, International Maritime Organization, Trichloroethylene, GHG, Gas, CO2, Capesize, Iron ore, Fuel oil, Index, LNG

Peter Norfolk, Editorial Director, Global Shipping & Freight, S&P Global Platts said:"The International Maritime Organization has set targets to cut total GHG emissions annually by 50% through 2050 compared with 2008 and reduce CO2 emissions by 40% by 2030.

Key Points:

Peter Norfolk, Editorial Director, Global Shipping & Freight, S&P Global Platts said:"The International Maritime Organization has set targets to cut total GHG emissions annually by 50% through 2050 compared with 2008 and reduce CO2 emissions by 40% by 2030.
NMAX GT4 is the dry bulk freight market's first alternative-fuel based weighted average index capturing the global trade on Newcastlemax bulkers, reflecting an important segment of the global dry bulk market that is expected to evolve in future.
Platts NMAX GT4 is based on an allocated weighting to the daily Time Charter Equivalent (TCE) assessments of four key voyages.
Platts Newcastlemax TCE assessments ($/day) are derived from related Capesize voyage charter prices ($/mt).

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

Retrieved on:

Wednesday, January 5, 2022

The fireside chat will be available for on-demand viewing beginning January 10, at 7:00 a.m.

Key Points:

The fireside chat will be available for on-demand viewing beginning January 10, at 7:00 a.m.
An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer.
Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations.

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

Retrieved on:

Tuesday, November 9, 2021

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.

Key Points:

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.
In the third quarter, we continued to utilize our novel TRACTr and TRACIr platforms to advance our pipeline of next generation immunotherapies.
RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
TRACTr product candidates advancing as planned.
THIRD QUARTER 2021 FINANCIAL HIGHLIGHTS:
Cash and cash equivalents and short-term investments: As of September 30, 2021, Janux reported cash and cash equivalents and short-term investments of $387.5 million, compared to $7.8 million at December 31, 2020.

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

Retrieved on:

Monday, November 8, 2021

An archived replay of both webcasts will be available on the website for approximately 90 days following the presentation.

Key Points:

An archived replay of both webcasts will be available on the website for approximately 90 days following the presentation.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer.
Januxs initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets.
Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations.

Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting

Retrieved on:

Thursday, November 4, 2021

SAN DIEGO and SUZHOU, China, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced publication of two abstracts featuring preclinical data from its expanding pipeline in advance of the 63rd ASH Annual Meeting & Exposition.

Key Points:

Specifically, by targeting novel epitopes and introducing conditionally-activated masking technology, Adagene develops antibody candidates with tailor-made safety and efficacy profiles.
Both ADG152 and ADG153 are potential Investigational New Drug candidates from Adagenes growing portfolio of preclinical discovery programs, five of which are in IND-enabling studies.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Retrieved on:

Thursday, October 7, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (Amunix), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients suffering from cancer, today announced that preclinical data from its lead program, AMX-818 (HER2-XPAT), were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. The collective data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. AMX-818 is largely stable in plasma and healthy tissue, yet efficiently cleaved to yield an active TCE in the tumor microenvironment. Amunix expects to file a CTA for AMX-818 by the end of 2021.

Key Points:

The collective preclinical data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart.
Amunix expects to file a Clinical Trial Application (CTA) for AMX-818 by the end of 2021.
The collective data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart.
Along with several other T cell engager programs, Amunix is also applying its proprietary masking technology to its first masked, protease-activated cytokine program, IL12-XPAC, which is in lead optimization.

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

Retrieved on:

Thursday, September 9, 2021

Biotechnology, Pharmaceutical, Health, Oncology

Ms. McNulty has more than 30 years of experience in finance and business development for private and publicly traded biopharmaceutical companies.

Key Points:

Ms. McNulty has more than 30 years of experience in finance and business development for private and publicly traded biopharmaceutical companies.
The Board and I welcome their complementary expertise as we continue to build the Company and look to advance our programs into the clinic.
Prior to Medikine he cofounded XenoPort, Inc., where he was the CEO and a Director for more than 15 years.
Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations.

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

Retrieved on:

Tuesday, September 7, 2021

Oncology, Health, Research, Pharmaceutical, Science, Biotechnology

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021.

Key Points:

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference being held September 13 to 15, 2021.
The corporate presentation will be available for on-demand viewing beginning September 13, 2021, at 7:00 a.m.
An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.
Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations.

Toxic Water Contamination Victims & Veterans Groups Call on Congress to Urgently Pass the Camp Lejeune Justice Act of 2021

Retrieved on:

Tuesday, August 24, 2021

In a letter sent to the U.S. House Armed Services Committee, the group called on Congress to pass the Camp Lejeune Justice Act of 2021 (H.R.

Key Points:

In a letter sent to the U.S. House Armed Services Committee, the group called on Congress to pass the Camp Lejeune Justice Act of 2021 (H.R.
"For too long, Veterans who served our country bravely have suffered from the devastating impacts of toxic water.
"The Camp Lejeune Justice Act of 2021 will finally bring relief and justice to the veterans and their families living in North Carolina.
Lejeune Justice is a group of civilians, military families, veterans, and advocates who are fighting for justice on behalf of toxic water contamination victims who lived and/or worked at Camp Lejeune in Jacksonville, North Carolina from 1953 through 1987.

Janux Therapeutics Reports Second Quarter 2021 Financial Results

Retrieved on:

Tuesday, August 10, 2021

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today reported financial results for the quarter ended June 30, 2021.

Key Points:

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today reported financial results for the quarter ended June 30, 2021.
Janux continues to expect to submit at least two Investigational New Drug (IND) applications by the end of 2022.
Second Quarter 2021 Financial Highlights:
Cash and cash equivalents and short-term investments: As of June 30, 2021, Janux reported cash and cash equivalents and short-term investments of $394.2 million, compared to $7.8 million at December 31, 2020.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer.